SMO and medulloblastoma: Herein, we have assessed transcriptomic public records of two microarray datasets and found that YAP1 is explicitly overexpressed in patients profiled as poor responders to SMO inhibitors (e.g., Sonidegib, Vismodegib) and in SHH medulloblastoma subtype alpha.